Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study

Abstract

AimsSecond-generation antipsychotics are an important component in the management of psychiatric conditions but their use can also lead to weight gain, diabetes, and dyslipidemia. Thus, this study aimed to assess the magnitude of metabolic syndrome and its predictors among patients who were on second-generation antipsychotic drugs at six psychiatry Hospitals, in Addis Ababa, Ethiopia, 2019. MethodThis study was conducted using a Multicenter cross-sectional study design. Medical charts of 510 patients on second-generation antipsychotic drugs who were selected by convenience sampling method and complete patients' charts were included in this study. Data was gathered using a checklist from patients’ medical charts. To identify the determinants of metabolic syndrome, a logistic regression model was used. ResultFrom a total of 510 patients’ Medical charts on the second-generation antipsychotic drugs, 270 (52.9%) of them were females and 240 (47.1%) were males. The magnitude of metabolic syndrome among patients receiving second-generation antipsychotic drugs was found to be 88 (17.8%). Age, education, family history of cardiovascular disease, and type of second-generation antipsychotic drugs are found to be significantly associated factors with metabolic syndrome. ConclusionsConsiderable proportion of patients receiving second-generation antipsychotic medications have metabolic syndrome.